Next Generation Sequencing test, coverage of >170 variants in 17 genes frequently mutated in cancer
Includes MSI for selection of anti-PD1 therapy. Includes detection of SNV, Fusion, CNV, INDELS and MSI. Input includes both ctDNA and ctRNA allowing for optimal fusion detection including, novel fusions.
Includes EGFR T790M and EGFR C797S variant detection for drug
Includes microsatellite instability (MSI) status for checking if a tumor will respond to anti-PD-1 therapy.
MSI status is determined by detecting the length of mononucleotide repeats at five genomic sites (BAT-25, BAT-26, NR-21, NR-24, and NR-27)
|Suitable For:||Individuals diagnosed with cancer|
|Lab Certification:||CAP / CLIA|
|TAT:||5 – 7 working days upon receipt of sample at Laboratory|